24/7 Market News Snapshot 06 February, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)

February 6, 2025

DENVER, Colo., 06 February, 2025 (247marketnews.com) – (NASDAQ:RNAZ) are discussed in this article.
TransCode Therapeutics, Inc. (RNAZ) is experiencing significant momentum as it advances its clinical initiatives, evidenced by a notable 29.52% surge in pre-market trading, with shares currently valued at $11.579, up from $8.940 at yesterday’s close. This uptick, driven by an impressive trading volume of 1.46 million shares, highlights growing investor enthusiasm and optimism about the company’s innovative cancer treatment solutions.

The surge in interest comes on the heels of TransCode announcing the successful enrollment and dosing of three patients in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, its lead therapeutic candidate. This trial aims to assess the safety and tolerability of TTX-MC138 in patients suffering from various metastatic solid tumors. The Safety Review Committee has unanimously endorsed the initiation of this third cohort, based on favorable safety and pharmacokinetic results from earlier cohorts, with no significant safety concerns reported among the nine participants thus far.

TTX-MC138 employs a pioneering approach by targeting microRNA-10b, a biomarker implicated in the progression of metastatic cancers. Early analyses from the trial indicate a strong pharmacokinetic and pharmacodynamic profile that aligns with prior preclinical data. Notably, Cohort 1 demonstrated a robust 66% inhibition of microRNA-10b within 24 hours post-infusion, while results from Cohort 2 suggested heightened therapeutic activity with increased dosing.

As this Phase 1 trial continues, it aims to provide essential insights into the safety and potential anticancer effects of TTX-MC138, paving the way for further development stages. TransCode Therapeutics remains dedicated to revolutionizing cancer treatment through its groundbreaking RNA therapies, and further updates will be anticipated as the company progresses in this crucial area of oncology.

Related news for (RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.